Targeting HIV: Antiretroviral therapy and development of drug resistance

Trends in Pharmacological Sciences

Volumn 23, Issue 8, 2002, Pages 381-388

  Menéndez Arias, Luis ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; FOSCARNET; INDINAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; NUCLEOSIDE; RITONAVIR; SAQUINAVIR; STAVUDINE; TALVIRALINE; TENOFOVIR DISOPROXIL; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CHEMOTHERAPY; GENE MUTATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MOLECULAR BIOLOGY; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; VIRUS RESISTANCE;

ANIMALS; ANTI-HIV AGENTS; DRUG RESISTANCE, MICROBIAL; HIV; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 0036696712     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-6147(02)02054-0     Document Type: Review

References (60)

1. Larder B.A., et al. HIV with reduced sensitivity to zidovudine isolated during prolonged therapy. Science. 243:1989;1731-1734.
2. Gulick R.M., et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. New Engl. J. Med. 337:1997;734-739.
3. Hammer S.M., et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. New Engl. J. Med. 337:1997;725-733.
4. Perelson A.S., et al. Decay characteristics of HIV-1 infected compartments during combination therapy. Nature. 387:1997;188-191.
5. Wong J.K., et al. Reduction of HIV-1 in blood and lymph nodes following potent antiretroviral therapy and the virologic correlates of treatment failure. Proc. Natl. Acad. Sci. U. S. A. 94:1997;12574-12579.
6. Finzi D., et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science. 278:1997;1295-1300.
7. Zhang L., et al. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. New Engl. J. Med. 340:1999;1605-1613.
8. Günthard H.F., et al. Evolution of envelope sequences of human immunodeficiency virus type 1 in cellular reservoirs in the setting of potent antiviral therapy. J. Virol. 73:1999;9404-9412.
9. Ramratnam B., et al. The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy. Nat. Med. 6:2000;82-85.
10. Chun T.-W., et al. Relationship between pre-existing viral reservoirs and the re-emergence of plasma viremia after discontinuation of highly active anti-retroviral therapy. Nat. Med. 6:2000;757-761.
11. Brooks D.G., et al. Generation of HIV latency during thymopoiesis. Nat. Med. 7:2001;459-464.
12. Kohlstaedt L.A., et al. Crystal structure at 3.5 Å resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science. 256:1992;1783-1790.
13. Arts E.J., Wainberg M.A. Mechanisms of nucleoside analog antiviral activity and resistance during human immunodeficiency virus reverse transcription. Antimicrob. Agents Chemother. 40:1996;527-540.
14. Huang H., et al. Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance. Science. 282:1998;1669-1675.
15. Sarafianos S.G., et al. Lamivudine (3TC) resistance in HIV-1 reverse transcriptase involves steric hindrance with β-branched amino acids. Proc. Natl. Acad. Sci. U. S. A. 96:1999;10027-10032.
16. Arion D., Parniak M.A. HIV resistance to zidovudine: the role of pyrophosphorolysis. Drug Resist. Updates. 2:1999;91-95.
17. Meyer P.R., et al. A mechanism of AZT resistance: an increase in nucleotide-dependent primer unblocking by mutant HIV-1 reverse transcriptase. Mol. Cell. 4:1999;35-43.
18. Mas A., et al. Role of a dipeptide insertion between codons 69 and 70 of HIV-1 reverse transcriptase in the mechanism of AZT resistance. EMBO J. 19:2000;5752-5761.
19. Boyer P.L., et al. Selective excision of AZTMP by drug-resistant human immunodeficiency virus reverse transcriptase. J. Virol. 75:2001;4832-4842.
20. Meyer P.R., et al. Differential removal of thymidine nucleotide analogues from blocked DNA chains by human immunodeficiency virus reverse transcriptase in the presence of physiological concentrations of 2′-deoxynucleoside triphosphates. Antimicrob. Agents Chemother. 44:2000;3465-3472.
21. Coakley E.P., et al. Phenotypic and genotypic resistance patterns of HIV-1 isolates derived from individuals treated with didanosine and stavudine. AIDS. 14:2000;F9-F15.
22. Balzarini J. Suppression of resistance to drugs targeted to human immunodeficiency virus reverse transcriptase by combination therapy. Biochem. Pharmacol. 58:1999;1-27.
23. De Clercq E. Perspectives of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection. Il Farmaco. 54:1999;26-45.
24. Ren J., et al. Structural mechanisms of drug resistance for mutations at codons 181 and 188 in HIV-1 reverse transcriptase and the improved resilience of second generation non-nucleoside inhibitors. J. Mol. Biol. 312:2001;795-805.
25. Ren J., et al. Binding of the second generation non-nucleoside inhibitor S-1153 to HIV-1 reverse transcriptase involves extensive main chain hydrogen bonding. J. Biol. Chem. 275:2000;14316-14320.
26. Fujiwara T., et al. S-1153 inhibits replication of known drug-resistant strains of human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 42:1998;1340-1345.
27. Mellors J., et al. Novel mutations in the reverse transcriptase of human immunodeficiency virus type 1 reduce susceptibility to foscarnet in laboratory and clinical isolates. Antimicrob. Agents Chemother. 39:1995;1087-1092.
28. Boden D., Markowitz M. Resistance to human immunodeficiency virus type 1 protease inhibitors. Antimicrob. Agents Chemother. 42:1998;2775-2783.
29. Huff J.R., Kahn J. Discovery and clinical development of HIV-1 protease inhibitors. Adv. Protein Chem. 56:2001;213-251.
30. Berkhout B. HIV-1 evolution under pressure of protease inhibitors: climbing the stairs of viral fitness. J. Biomed. Sci. 6:1999;298-305.
31. Molla A., et al. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat. Med. 2:1996;760-766.
32. Zhang Y.M., et al. Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites. J. Virol. 71:1997;6662-6670.
33. Condra J.H., et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature. 374:1995;569-571.
34. Hertogs K., et al. Phenotypic and genotypic analysis of clinical HIV-1 isolates reveals extensive protease inhibitor cross-resistance: a survey of over 6000 samples. AIDS. 14:2000;1203-1210.
35. Sham H.L., et al. ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease. Antimicrob. Agents Chemother. 42:1998;3218-3224.
36. Coffin J.M. HIV population dynamics in vivo: implications for genetic variation, pathogenesis and therapy. Science. 267:1995;483-489.
37. Ho D.D., et al. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature. 373:1995;123-126.
38. Wei X., et al. Viral dynamics in human immunodeficiency virus type-1 infection. Nature. 373:1995;117-122.
39. Menéndez-Arias L. Molecular basis of fidelity of DNA synthesis and nucleotide specificity of retroviral reverse transcriptases. Progr. Nucleic Acid Res. Mol. Biol. 71:2002;91-147.
40. Shirasaka T., et al. Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides. Proc. Natl. Acad. Sci. U. S. A. 92:1995;2398-2402.
41. Winters M.A., et al. A 6-basepair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers resistance to multiple nucleoside inhibitors. J. Clin. Invest. 102:1998;1769-1775.
42. Markowitz M. Resistance, fitness, adherence, and potency - mapping the paths to virologic failure. J. Am. Med. Assoc. 283:2000;250-251.
43. Wong J.K., et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science. 278:1997;1291-1295.
44. Pomerantz R.J. Reservoirs of human immunodeficiency virus type 1: the main obstacles to viral eradication. Clin. Infect. Dis. 34:2002;91-97.
45. Ribeiro R.M., Bonhoeffer S. Production of resistant HIV mutants during antiretroviral therapy. Proc. Natl. Acad. Sci. U. S. A. 97:2000;7681-7686.
46. St Clair M.H., et al. Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science. 253:1991;1557-1559.
47. Larder B.A. 3′-Azido-3′-deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitors. Antimicrob. Agents Chemother. 36:1992;2664-2669.
48. Gu Z., et al. K65R mutation of human immunodeficiency virus type 1 reverse transcriptase encodes cross-resistance to 9-(2-phosphonylmethoxyethyl)adenine. Antimicrob. Agents Chemother. 39:1995;1888-1891.
49. Tachedjian G., et al. Zidovudine resistance is suppressed by mutations conferring resistance of human immunodeficiency virus type 1 to foscarnet. J. Virol. 70:1996;7171-7181.
50. Götte M., et al. The M184V mutation in the reverse transcriptase of human immunodeficiency virus type 1 impairs rescue of chain-terminated DNA synthesis. J. Virol. 74:2000;3579-3585.
51. Kemp S.D., et al. A novel polymorphism at codon 333 of human immunodeficiency virus type 1 reverse transcriptase can facilitate dual resistance to zidovudine and l-2',3′-dideoxy-3′-thiacytidine. J. Virol. 72:1998;5093-5098.
52. Moore J.P., Stevenson M. New targets for inhibitors of HIV-1 replication. Nat. Rev. Mol. Cell Biol. 1:2000;40-49.
53. De Clercq E. New developments in anti-HIV chemotherapy. Curr. Med. Chem. 8:2001;1543-1572.
54. De Clercq E. Strategies in the design of antiviral drugs. Nat. Rev. Drug Discovery. 1:2002;13-25.
55. Parikh, U. et al. (2000) Mutations in retroviral genes associated with drug resistance. In HIV Sequence Compendium 2000 (Kuiken, C. et al., eds.), pp. 106-161, Theoretical Biology and Biophysics Group, Los Alamos National Laboratory
56. Kilby J.M., et al. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat. Med. 4:1998;1302-1307.
57. Eckert D.M., Kim P.S. Mechanisms of viral membrane fusion and its inhibition. Annu. Rev. Biochem. 70:2001;777-810.
58. Derdeyn C.A., et al. Sensitivity of human immunodeficiency virus type 1 to fusion inhibitors targeted to the gp41 first heptad repeat involves distinct regions of gp41 and is consistently modulated by gp120 interactions with the coreceptor. J. Virol. 75:2001;8605-8614.
59. Menéndez-Arias L., Domingo E. (2002) Amino acid substitutions associated with resistance to HIV-1 reverse transcriptase inhibitors, protease inhibitors, and other antiretroviral drugs. In Guide to Management of HIV Drug Resistance and Pharmacokinetics of Antiretroviral Therapy (2nd edition) (Clotet, B. et al., eds). pp. 37-112. Ed. Taisa S.L., Barcelona, Spain.
60. Menéndez-Arias L. (2002) Sensitivity to reverse transcriptase and protease inhibitors of recombinant HIV clones harboring resistance mutations: in vitro studies. In Guide to Management of HIV Drug Resistance and Pharmacokinetics of Antiretroviral Therapy (2nd edn) (Clotet, B. et al., eds.). pp. 113-202. Ed. Taisa S.L., Barcelona, Spain.